Severe acute respiratory syndrome (SARS), a contagious and fatal respiratory illness, was first reported in Guangdong province, China, in November 2002.[@bib1] Its rapid and unexpected spread to other Asian countries, North America, and Europe alarmed both the public and the World Health Organization. SARS is caused by a novel coronavirus, SARS-CoV.[@bib2], [@bib3] Its emergence affected more than 8000 individuals and caused more than 800 deaths within a few months.[@bib4] This signifies just how rapidly a contagious illness can spread in the more mobile and highly interconnected world in the 21st century. Remarkably, the world has witnessed how concerted international cooperation allowed health experts to identify the novel etiologic agent and contain the SARS epidemic just months after its emergence. Currently, there is no known SARS transmission anywhere in the world. At the same time, there is no guarantee that this outbreak will not strike again in an even more severe form. Thus far, no effective therapy exists for this viral infection.

The SARS-CoV is a positive-strand RNA virus whose genome sequence reveals only moderate relation to other known coronaviruses.[@bib5] During viral replication, viral replicase polyproteins undergo extensive processing by two viral proteases, namely chymotrypsin-like protease (3CLpro) and papain-like protease (PLpro), to generate a functional viral replication complex.[@bib6], [@bib7] Therefore, both SARS-CoV 3CLpro and SARS-CoV PLpro are recognized as logical targets for therapeutic intervention against SARS-CoV and related interactions.[@bib8]

The structure and activity of the SARS-CoV 3CLpro have been investigated.[@bib9] The enzyme active site contains a catalytic dyad where a cysteine residue acts as a nucleophile and a histidine residue acts as the general acid base. SARS-CoV 3CLpro is functionally analogous to the main picornaviral protease 3Cpro and there have been significant drug-design efforts against human rhinoviral 3C protease which is also a cysteine protease.[@bib10] We recently described structure-based design of a number of potent SARS-CoV 3CLpro inhibitors.[@bib11] These inhibitors were designed based upon modification of AG7088, a potent inhibitor of the human rhinoviral 3C protease.[@bib12] While AG7088 does not exhibit inhibitory activity against SARS-CoV 3CLpro, the modified inhibitors are active in enzymatic assays as well as in cell culture assays.[@bib13] The X-ray structure of inhibitor-bound SARS-3CLpro revealed important molecular insight into the ligand-binding sites of enzyme.[@bib11] The inhibitors bind to SARS-CoV 3CLpro through covalent bonding with the active site cysteine 145 residue. Based upon this molecular insight, we have now modified our initial inhibitors to accommodate specific ligand-binding site interactions in the S~4~-subsite of the SARS-CoV 3CLpro active site. Herein we describe the synthesis, biological evaluation, and X-ray structures of inhibitor-bound SARS-CoV 3CLpro for two potent peptide and peptidomimetic inhibitors ([Fig. 1](#fig1){ref-type="fig"} ).Figure 1Structures of SARS-3CLpro inhibitors.

As described previously, inhibitor **2** makes a number of important interactions in the enzyme active site.[@bib11] These include, the covalent bond formed by the Cys-145 thiol with the α,β-unsaturated ester at the S~1~-subsite. His-172 makes hydrogen bond with the P~1~-lactam-NH, and the Glu-166 nitrogen makes a hydrogen bond with the ketone of the inhibitor.[@bib11] The P~4~-oxazole group appears to fill in the S~4~-hydrophobic pocket. Based upon this X-ray structure, we subsequently speculated that the replacement of P~4~-oxazole with a Boc-Serine P~4~-ligand would promote additional hydrogen-bonding interactions in the S~4~-site. This will result in further enhancement of inhibitory potency. We have also evaluated the corresponding peptide-derived inhibitors for our studies.

The synthesis of inhibitor **3** is outlined in [Scheme 1](#fig3){ref-type="fig"} . The synthetic procedure of silyl ether derivative **6** was described by us previously.[@bib11] Removal of the silyl protecting group with tetrabutylammonium fluoride in THF provided a secondary alcohol, which was oxidized to ketone **7** with the Dess--Martin periodinane in 73% yield over 2 steps. The ketone **7** was converted to inhibitor **3** by exposure to trifluoroacetic acid (20% TFA/CH~2~Cl~2~) followed by coupling of the resulting amine with Boc-(L)-Serine to provide **3** in 72% yield.Scheme 1Reagents: (a) TBAF, THF; (b) Dess--Martin periodinane, CH~2~Cl~2~, 73% (two steps); (c) TFA, CH~2~Cl~2~; (d) EDC, HOBt, DIPEA, Boc-(L)-Serine, CH~2~Cl~2~, 72%.

The syntheses of peptide-based inhibitors are summarized in [Scheme 2](#fig4){ref-type="fig"} . General peptide coupling reactions between (*S*)-valine and (*S*)-leucine or (*S*)-phenylalanine followed by ester hydrolysis gave the carboxylic acid intermediates **10** and **11** in 81% and 90% yields, respectively. Coupling of these acids with lactam fragment **12** [@bib11], [@bib14] afforded Boc-derivatives **13** and **14** in 89% and 86% yields, respectively. Exposure of these compounds to TFA effected the removal of the Boc-group to provide the corresponding free amines. Coupling of these amines with Boc-(L)-serine furnished inhibitors **4** and **5** in 55% and 95% yields, respectively. Furthermore, reaction of the **13** or **14**-derived amines with 5-methylisoxazole-3-carboxylic acid **15** [@bib15] afforded inhibitors **16** (75%) and **17** (81%) in very good yields.Scheme 2Reagents: (a) EDC, HOBt, DIPEA, Boc-(L)-valine, CH~2~Cl~2~; (b) LiOH (1 M in H~2~O), THF; (c) EDC, HOBt, DIPEA, **12**, CH~2~Cl~2~; (d) TFA, CH~2~Cl~2~; (e) EDC, HOBt, DIPEA, Boc-(L)-Serine, CH~2~Cl~2~; (f) EDC, HOBt, DIPEA, **15**, CH~2~Cl~2~.

The inhibitory activities of the synthetic inhibitors are shown in [Table 1](#tbl1){ref-type="table"} . The enzyme inhibitory activity of the compounds against SARS-CoV 3CLpro was determined in a FRET-based, microplate assay described by Grum-Tokars et al.[@bib11], [@bib16] This protocol has previously been used for the determination of IC~50~ values for α,β-unsaturated esters.[@bib17] The assays were performed in 96-well microplates using a reaction volume of 100 μL which contained 50 mM Hepes, (pH 7.5), 500 nM SARS-CoV 3CLpro enzyme, and varying concentrations of synthetic inhibitors. The reaction components, with the exception of substrate, were incubated for 20 min and the reaction was initiated by the addition of FRET-substrate \[AlexaFluor^®^ 488-cys\]-Glu-Ser-Ala-Thr-Leu-Gln-Ser-Gly-Leu-Ala-\[Lys-QSY^®^-7\]-Ser, giving a final substrate concentration of 1 μM.[@bib11], [@bib16] The IC~50~ values for inhibitors were determined by measuring the rates of reaction with increasing inhibitor concentrations. As shown in [Table 1](#tbl1){ref-type="table"}, our structure-based incorporation of P~4~-Boc-Ser in place of P~4~-oxazole in inhibitor **2** resulted in (inhibitor **3**) significant enhancement of enzymatic inhibitory potency, while its antiviral activity was not improved. It exhibited antiviral activity similar to inhibitors **1** and **2**. This difference of activity may be due to the presence of peptide-like features in the inhibitors. Peptide-like molecules often exhibit poor passive transcellular diffusion across cell membranes. Antiviral assays followed our previously published protocol.[@bib11], [@bib18] We have compared the binding affinity of the corresponding peptide-based inhibitors incorporating both P~4~-oxazole and P~4~-Boc Ser. Peptide-based inhibitors (**4** and **5**) with P~2~-Leu and P~2~-Phe have displayed 20-fold enzymatic potency enhancement over the respective inhibitors (**16** and **17**) containing P~4~-oxazole.Table 1Structures and activity of inhibitorsEntryInhibitor structure3CLpro, IC~50~ (μM)Antiviral, IC~50~ (μM)1.![](fx2.gif)870452.![](fx3.gif)800703.![](fx4.gif)80754.![](fx5.gif)101005.![](fx6.gif)151006.![](fx7.gif)300nd7.![](fx8.gif)200nd

To obtain molecular insight into the binding properties of inhibitor **3**, we determined the X-ray structure of **3**-bound to SARS-CoV 3CLpro to a resolution of 1.9 Å.[@bib19] The refinement statistics and data collection are summarized in [Table 2](#tbl2){ref-type="table"} . A stereoview of the inhibitor-bound structure is shown in [Figure 2](#fig2){ref-type="fig"} . The X-ray structure reveals that the inhibitor is covalently bonded to the enzyme via a C--S bond (1.77 Å) to the active site cysteine (Cys-145). The $\text{P}_{1}^{\prime}$-ethyl ester carbonyl is within proximity to Thr-26 oxygen (3.38Å). The Leu-27 side chain makes hydrophobic contacts with the $\text{P}_{1}^{\prime}$-ligand. Furthermore, the P~1~-lactam NH forms a hydrogen bond with the imidazole ring of His-163. The P~3~-carbonyl group of **3** forms a hydrogen bond with the NH of Glu-166. The P~4~-Ser side chain is within hydrogen-bonding distance of Glu 166. This may explain its enhanced binding affinity over the oxazole-bearing inhibitor **2**.Table 2Summary of X-ray data processing and refinement statisticsResolution (Å)*R*~merge~[b](#tblfn2){ref-type="table-fn"} (%)% Complete*a* (Å)*b* (Å)*c* (Å)*β* (deg)*R*~cryst~[c](#tblfn3){ref-type="table-fn"} (%)*R*~free~[d](#tblfn4){ref-type="table-fn"} (%)*R*~free~ after TLS*R*~free~ after TLS20.0--1.9 (1.97--1.90)[a](#tblfn1){ref-type="table-fn"}3.1 (21.7)91.5 (53.0)108.3282.2253.68104.6723.6 (33)27.5 (36)19.6 (28)22.8 (35)[^1][^2][^3][^4]Figure 2The X-ray crystal structure of **3** (thick stick with gray carbon) with SARS-CoV 3CLpro. Hydrogen bonds between inhibitor and 3CLpro are shown in white dotted lines.

In conclusion, our structure-based design strategies resulted in significant improvement of enzyme inhibitory activity against SARS-CoV 3CLpro. An X-ray structure of the **3**-bound enzyme provided critical molecular insight into the ligand-binding site interactions in the active site. It appears that the P~4~-Boc-Ser is involved in important hydrogen-bonding interactions in the $\text{S}_{4}^{\prime}$-subsite. The present molecular insight will facilitate the design of more effective inhibitors. Further investigations are in progress.
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[^1]: Last shell resolution statistics are shown within parentheses.

[^2]: *R*~merge~ = ∑∣*I* − 〈*I*〉∣/∑*I*, where *I* is the observed intensity and 〈*I*〉 is the average intensity of multiple symmetry-related observations of that reflection. 118,202 measured reflections. 31,114 unique reflections.

[^3]: *R*~cryst~ = ∑∣∣*F*~obs~∣ − ∣*F*~calc~∣∣/∑∣*F*~obs~∣, where ∣*F*~obs~∣ and ∣*F*~calc~∣ are the observed and calculated, respectively, structure factor amplitudes for each reflection.

[^4]: *R*~free~ is the same as *R*~cryst~, except it is calculated over a set of reflections not used in structural refinement at any stage (5% of the observed data in all cases).
